Proteomic Stroke Research
Thermo Fisher Scientific has announced the initial findings of stroke research conducted by its Biomarker Research Initiatives in Mass Spectrometry (BRIMS) centre in collaboration with Massachusetts General Hospital (MGH), Harvard University. According to the company, the research provides potentially significant insight into patent foramen ovale (PFO) and its connection with strokes.
Thermo Fisher Scientific has announced the initial findings of stroke research conducted by its Biomarker Research Initiatives in Mass Spectrometry (BRIMS) centre in collaboration with Massachusetts General Hospital (MGH), Harvard University. According to the company, the research provides potentially significant insight into patent foramen ovale (PFO) and its connection with strokes.
PFO is a congenital heart abnormality that leaves a passage open between the left and right sides of the heart, enabling blood clots to travel from the leg to the brain. The collaborative research has provided scientists with MS data, from which potential biomarkers have been identified. If confirmed, these may be useful in helping doctors to select the most appropriate treatment for individual PFO stroke patients.
The collaboration has also led to insights in the understanding of tissue plasminogen activator (tPA) in stroke treatment. tPA is a drug that can only be safely administered within a very short time after stroke symptoms occur. The treatment, which works by dissolving blood clots, has proven highly effective but only 5% of patients fit the criteria within which it is safe to administer tPA. Through the use of proteomics workflows, the data may someday help identify a wider scope of patients who might benefit from tPA.
This story originally appeared in The Column. Click here to view that issue.
Best of the Week: Food Analysis, Chemical Migration in Plastic Bottles, STEM Researcher of the Year
December 20th 2024Top articles published this week include the launch of our “From Lab to Table” content series, a Q&A interview about using liquid chromatography–high-resolution mass spectrometry (LC–HRMS) to assess chemical hazards in plastic bottles, and a piece recognizing Brett Paull for being named Tasmanian STEM Researcher of the Year.
Using LC-MS/MS to Measure Testosterone in Dried Blood Spots
December 19th 2024Testosterone measurements are typically performed using serum or plasma, but this presents several logistical challenges, especially for sample collection, storage, and transport. In a recently published article, Yehudah Gruenstein of the University of Miami explored key insights gained from dried blood spot assay validation for testosterone measurement.
Determination of Pharmaceuticals by Capillary HPLC-MS/MS (Dec 2024)
December 19th 2024This application note demonstrates the use of a compact portable capillary liquid chromatograph, the Axcend Focus LC, coupled to an Agilent Ultivo triple quadrupole mass spectrometer for quantitative analysis of pharmaceutical drugs in model aqueous samples.
